Tumors related to hereditary susceptibility seem to have an immunosensitive phenotype.
We conducted a multicenter retrospective study, to investigate if family history of cancer, multiple neoplasms and early onset of cancer could be related to clinical outcomes of anti-PD-1/PD-L1 therapy. Activity and efficacy data of 211 advanced cancer patients (kidney, non-small-cell lung cancer, melanoma, urothelium, colorectal and HeN), treated at seven Italian centers with anti-PD-1/PD-L1 agents, were analyzed.
In this preliminary report at multivariate analyses, positive family history of cancer showed a statistically significant relationship with a better objective response rate (p = 0.0024), disease control rate (p = 0.0161), median time to treatment failure (p = 0.0203) and median overall survival (p = 0.0221). Diagnosis of multiple neoplasms significantly correlates only to a better disease control rate, while interestingly non-early onset of cancer and sex (in favor of female patients) showed significant correlation with a better median overall survival (p = 0.0268 and p = 0.0272, respectively).
This pilot study seems to individuate easily available patient's features as possible predictive surrogates of clinical benefit for anti-PD-1/PD-L1 treatments. These preliminary results need to be confirmed with a greater sample size, in prospective trials with immunotherapy.
Immunotherapy. 2018 Mar 22 [Epub ahead of print]
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Elisabetta Gambale, Francesco Atzori, Federica Zoratto, Alessandro Parisi, Davide Brocco, Annagrazia Pireddu, Katia Cannita, Daniela Iacono, Maria R Migliorino, Teresa Gamucci, Michele De Tursi, Tina Sidoni, Maria Tiseo, Maria Michiara, Anselmo Papa, Gesuino Angius, Silverio Tomao, Maria C Fargnoli, Clara Natoli, Corrado Ficorella
Medical Oncology Unit, St Salvatore Hospital, Department of Biotechnological & Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy., Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Medical Oncology Unit, SS Annunziata Hospita, Chieti, Italy., Medical Oncology Unit, University Hospital of Cagliari, Cagliari, Italy., Medical Oncology Unit, F. Spaziani Hospital, Frosinone, Italy., Pulmonary Oncology Unit, St. Camillo Forlanini Hospital, Rome, Italy., Department of Medico-Surgical Sciences & Biotechnologies, University of Rome 'Sapienza', Latina, Italy., Oncology Unit, Department of Radiological Sciences, Oncology & Pathology, University of Rome 'Sapienza', Latina, Italy., Oncological Dermatology Unit, San Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.